1. Home
  2. MAYA vs XGN Comparison

MAYA vs XGN Comparison

Compare MAYA & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAYA
  • XGN
  • Stock Information
  • Founded
  • MAYA 2024
  • XGN 2002
  • Country
  • MAYA United States
  • XGN United States
  • Employees
  • MAYA N/A
  • XGN N/A
  • Industry
  • MAYA
  • XGN Medical Specialities
  • Sector
  • MAYA
  • XGN Health Care
  • Exchange
  • MAYA NYSE
  • XGN Nasdaq
  • Market Cap
  • MAYA 150.3M
  • XGN 138.3M
  • IPO Year
  • MAYA 2025
  • XGN 2019
  • Fundamental
  • Price
  • MAYA $10.09
  • XGN $7.00
  • Analyst Decision
  • MAYA
  • XGN Strong Buy
  • Analyst Count
  • MAYA 0
  • XGN 2
  • Target Price
  • MAYA N/A
  • XGN $7.50
  • AVG Volume (30 Days)
  • MAYA 479.0
  • XGN 237.8K
  • Earning Date
  • MAYA 01-01-0001
  • XGN 08-04-2025
  • Dividend Yield
  • MAYA N/A
  • XGN N/A
  • EPS Growth
  • MAYA N/A
  • XGN N/A
  • EPS
  • MAYA N/A
  • XGN N/A
  • Revenue
  • MAYA N/A
  • XGN $56,724,000.00
  • Revenue This Year
  • MAYA N/A
  • XGN $19.39
  • Revenue Next Year
  • MAYA N/A
  • XGN $13.27
  • P/E Ratio
  • MAYA N/A
  • XGN N/A
  • Revenue Growth
  • MAYA N/A
  • XGN 1.78
  • 52 Week Low
  • MAYA $10.03
  • XGN $1.71
  • 52 Week High
  • MAYA $10.65
  • XGN $7.95
  • Technical
  • Relative Strength Index (RSI)
  • MAYA N/A
  • XGN 52.23
  • Support Level
  • MAYA N/A
  • XGN $6.62
  • Resistance Level
  • MAYA N/A
  • XGN $7.35
  • Average True Range (ATR)
  • MAYA 0.00
  • XGN 0.48
  • MACD
  • MAYA 0.00
  • XGN -0.10
  • Stochastic Oscillator
  • MAYA 0.00
  • XGN 29.63

About MAYA MAYWOOD ACQUISITION CORP

Maywood Acquisition Corp is a blank check company.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: